 |
 |
------ =_NextPart_000_01BC91F3.515C1180 Content-Type: text/plain; charset="us-ascii" Content-Transfer-Encoding: 7bit Phil, I was prescribed permax at the end of May this year, because I had been experiencing a lot of fluctuations in the efficacy of the levadopa (I take Madopar, here in Australia) I was taking. I had a lot of "off" periods during the day, frequent and often for quite long times. I also take selegeline with breakfast and lunch. Anyway, I started the permax as suggested, first day 0.05 mg, then 0.15, 0.25, 0.35, 0.45, 0.60, 0.75, staying at each level for 2 days. However, by the time I reached the morning of day 6, I was so nauseous that I was continually vomiting. The neuro suggested stopping the permax and restarting in a few days, this time at my own pace. So, I waited 3 days and then started again with 0.05mg, but building up the dosage ever so slowly, much more slowly than recommended. I managed, without recurrence of nausea, to get eventually to 3 tablets of 0.25 mg each, after breakfast, after lunch, after tea. I am much better now than I was before the permax. I have times when I am slow and very tired, but not the dreadful "off" times I had before. Please note, however, that permax seemed to compound the effect that selegeline (deprenyl) has in lowering my blood pressure. At least, that's how my doctor explained my extraordinary tiredness. This tiredness eased somewhat when I made sure I took the selegeline right at the beginning of the meal and the permax a little after, thus spacing the two medications. Also, sad to say, permax does increase my tendency to constipation. This is merely a personal, non-medical account of how permax effected and ultimately helped me. Regards Robyn. (Age 48, diag 7 yrs) ------ =_NextPart_000_01BC91F3.515C1180 Content-Type: application/ms-tnef Content-Transfer-Encoding: base64 eJ8+IjAGAQaQCAAEAAAAAAABAAEAAQeQBgAIAAAA5AQAAAAAAADoAAENgAQAAgAAAAIAAgABBJAG AFABAAABAAAADAAAAAMAADADAAAACwAPDgAAAAACAf8PAQAAAFwAAAAAAAAAgSsfpL6jEBmdbgDd AQ9UAgAAAABQYXJraW5zb24ncyBJbmZvcm1hdGlvbiBFeGNoYW5nZQBTTVRQAFBBUktJTlNOQGxp c3RzZXJ2LnV0b3JvbnRvLmNhAB4AAjABAAAABQAAAFNNVFAAAAAAHgADMAEAAAAeAAAAUEFSS0lO U05AbGlzdHNlcnYudXRvcm9udG8uY2EAAAADABUMAQAAAAMA/g8GAAAAHgABMAEAAAAjAAAAJ1Bh cmtpbnNvbidzIEluZm9ybWF0aW9uIEV4Y2hhbmdlJwAAAgELMAEAAAAjAAAAU01UUDpQQVJLSU5T TkBMSVNUU0VSVi5VVE9ST05UTy5DQQAAAwAAOQAAAAALAEA6AQAAAAIB9g8BAAAABAAAAAAAAAOw RgEIgAcAGAAAAElQTS5NaWNyb3NvZnQgTWFpbC5Ob3RlADEIAQSAAQAXAAAARXhwZXJpZW5jZSB3 aXRoIHBlcm1heACRCAEFgAMADgAAAM0HBwAQAA4AEgAhAAMALwEBIIADAA4AAADNBwcAEAANADcA LAADAF4BAQmAAQAhAAAAN0I2QkZGMThEOEZERDAxMTlDRTE0NDQ1NTM1NDAwMDAAFgcBA5AGALQG AAASAAAACwAjAAEAAAADACYAAAAAAAsAKQABAAAAAwA2AAAAAABAADkAYMAtFrCRvAEeAHAAAQAA ABcAAABFeHBlcmllbmNlIHdpdGggcGVybWF4AAACAXEAAQAAABYAAAABvJGwFi0Y/2t8/dgR0Jzh REVTVAAAAAAeAB4MAQAAAAUAAABTTVRQAAAAAB4AHwwBAAAAEgAAAGpvbnJvYkBvbnMuY29tLmF1 AAAAAwAGEGcn5SkDAAcQJwUAAB4ACBABAAAAZQAAAFBISUwsSVdBU1BSRVNDUklCRURQRVJNQVhB VFRIRUVORE9GTUFZVEhJU1lFQVIsQkVDQVVTRUlIQURCRUVORVhQRVJJRU5DSU5HQUxPVE9GRkxV Q1RVQVRJT05TSU5USEVFRkYAAAAAAgEJEAEAAAA/BQAAOwUAAFIIAABMWkZ1M6I/fP8ACgEPAhUC pAPkBesCgwBQEwNUAgBjaArAc2V07jIGAAbDAoMyA8YHEwKDujMTDX0KgAjPCdk7Ff94MjU1AoAK gQ2xC2Bu8GcxMDMUIAsKFCIMASJjAEAgUGgDECwg0Ekgd2EEIHAWAATyHmIJgBuQBJAAwHggYWEF QHRoZSAJ8BwwbzJmBdBheRzhBAAgeY5lCsAbIBwQY2F1EfB/GzAKhRHAHDAcEAnwHSB4UxxRCJBu YwuAZxywIA8VkAVAHXEY0HVjdHV9HMBpAiAEIAuAHOQN0GkdHrBjHcAdcRzybGV2bR+gbwqwCoUo G0ABkGt/HRAdoCQCHmEdABYAIkJB2R7QdHIHQAcwKRs1JOFdILEuGzEfkiD3Ih1wZt4iCoUgQgRw BCBkCHEgwZ0c8mQdsBsgA1BlcQpQ9wIwHLAdQ3Qf8QIQBcArMH5pK/AhASpCB3InsgdAc95vCoUk 4xHwI8BnLsALgL8dEAPwHPAegBYAJPBmG3BnK3QKQCCQaC4KhQqFQfxueRtgKtEbQCZgCsAr8I8c MBzyHFYEIHN1Zy7wdyZgCYAq4WkR4AVAKrEggDAuMDUgbWcbIM0c8W4KhTUgMTUbIDUgKxgwNqIz NpM0NpM2MO02ojc2kTJxeSCzBUAeQP8RsCOyLsAsIxIgKrEtYAqF+EhvdzmxHmIdwh0QLSL/GzEv wRGwMsUEYASgILIdcd004jYbJi3QMVZuHsIIYP8nMRHABUAbRAWgAjALgCHQdGxsHcB2A3AskCeD VP8dAS8wCHA+4DPXCoUmYCQQ/nAqNhxWHUEbsTKCILIiUf0g8GYH0TpiNZIeATwjHME8bXkKhTsw A6AKsGNluSewU28bJCyRHDAzOlPnK4M1sjJnYWcLcS9UNSJzNXEKhWJ1BUBMsAMQZMkgsnVwKmRv c0sgHRFrO2E+wnMVkHdBQBsgbf8hoC+QPVEukU7zP/I15hYA/QWgbQeAHUAJgCeyA4FOIf80US9i CGAFQFEhCHAWACCQdx0QHXE/c2E1kT7gLvB0/wqFObECMEEUVIFJoAGRI8B+dAQgHXE2wjVhOUMb IGH/K+FMkS/GV8Ywk0w2V+Qr8O5hJ7Aw/C2RbU9UHBACQP1OgW47MFBjGzUcECwxPAHfMwcntDnA LRQKhXdKYluz/07iK4M7YR3BNJA0QkyyXMDFHNRkL8FkZnUDICjD7y0UHw1d0iewUCPAG3BCMX0h IGUloTs2QAMcVRHwZe8HgDLRPuBRQXAIYB1ALfbfIpQFkBzSHMEuuSgNsBuh/THgbCbQEcAiM07x BnEgwf9HoB6AFZAEcBuTM9BlETFm7wVAZWJYwUACJwQgZiFsUv8kACGwBbEgIQtiHCFsYSAg/yZx BbBNMQrAYXUvMAQQMOb/QhBG83G1OUER8BwwLdAHgP9gEBzBYBUAwA2wM8El4STBHWywaxzjLrhQ tmlnaPcrcRzUHBBnC4A9hj0THkDfAyBKFRxHIQAskHQjwFfUnzWSHtBDRkhxKjZ0dz7g72ehIvEh 8yewQS3BOIEfof9UgU4QKtEcVSQAB5ELgAUA/2VyCoVsYSvxDbAgkFXjQLH/JmAFICHjMO1yox4B B4AWAH9BQSDwHFEt0D9wGxFcwG72LX0keWFjBaAwoCEzbwL/HFVpREMnK5JjIC0hHMCEEr0dAGwc UHBhbWcKhVIu4HcLEV+WiiZvO7CCYCSgQTlOMTQ4GyBNMEsgIDd7HiAR4Ckw/I4PCrgmoDMvOAAZ vDFWFSEAkhAAAwAQEAAAAAADABEQAAAAAEAABzBgck/mrJG8AUAACDBgck/mrJG8AR4APQABAAAA AQAAAAAAAADADw== ------ =_NextPart_000_01BC91F3.515C1180--